Oncolytics Biotech (ONCY) EBITDA Margin (2009 - 2025)

Oncolytics Biotech's (ONCY) quarterly EBITDA Margin came in at 14337.81% in Q3 2025, up 4940031.0% year-on-year from N/an in Q3 2024, and up 140.89% on a QoQ basis from 35062.5% in Q3 2024.

Oncolytics Biotech (ONCY) EBITDA Margin (2009 - 2025) Analysis & Trends

Oncolytics Biotech (ONCY) has 10 years of EBITDA Margin data on file, last reported at 14337.81% in Q3 2025.

  • On a quarterly basis, EBITDA Margin rose 4940031.0% year-over-year to 14337.81% in Q3 2025; TTM through Sep 2025 was 42.67%, a 3511.0% decrease from a year earlier, with the FY2018 full-year figure at 97.36%, changed N/A from the prior year.
  • EBITDA Margin for Q3 2025 stood at 14337.81%, up from 35062.5% in the prior quarter.
  • Over the last five years, EBITDA Margin for ONCY reached as high as 14337.81% in Q3 2025 and fell as low as 35062.5% in Q3 2024.
Generated on {Timestamp} © BusinessQuant.com
Generated on {Timestamp} Powered by BusinessQuant Logo

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) EBITDA Margin (Qtr)
1 Oculis Holding AG 66,621.14 Bn 66,620.85 Bn - -
2 Nanobiotix 1,915.18 Bn 1,915.11 Bn - -
3 Akari Therapeutics 1,014.18 Bn 1,014.18 Bn - -
4 BeOne Medicines 471.27 Bn 466.48 Bn 1.35 Bn 16.51%
5 Vertex Pharmaceuticals 121.81 Bn 114.57 Bn 2.59 Bn 38.10%
6 Regeneron Pharmaceuticals 69.58 Bn 60.82 Bn 3.31 Bn 17.83%
7 Belite Bio 62.72 Bn 62.72 Bn - -
8 Argenx Se 55.51 Bn 50.33 Bn 1.41 Bn 31.68%
9 Revolution Medicines 37.35 Bn 37.35 Bn - -
10 Oncolytics Biotech 76.93 Mn 76.93 Mn - -

Historic Data

Download Data
DateValue
Sep 30, 2025 14,337.81%
Sep 30, 2024 -35,062.50%
Sep 30, 2020 -16.33%
Jun 30, 2020 -14.50%
Sep 30, 2019 -28.18%
Jun 30, 2019 -43.10%
Mar 31, 2019 0.00%
Dec 31, 2018 34.09%
Sep 30, 2018 20,877.66%
Jun 30, 2017 0.00%
Jun 30, 2016 368.32%
Jun 30, 2011 471.50%
Sep 30, 2010 2,106.77%
Jun 30, 2010 -623.44%
Dec 31, 2009 -5,228.79%
Sep 30, 2009 27.90%
Jun 30, 2009 36.17%
Mar 31, 2009 42.59%